MYOM2 and Miyoshi myopathy: Patients identified as high risk by any of these models (e.g. IMWG identified high-risk as patients with 50% progression risk at 2 years from diagnosis based on the levels of M-protein, BMPC infiltration, or sFLC ratio) should be considered to have an increased risk of progression to active MM.